Drug Patents Expiring in 2033
1. Abilify Asimtufii patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11638757 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US10517951 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US11097007 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 27 April, 2023
Treatment: Maintenance monotherapy treatment of bipolar i disorder; Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ABILIFY ASIMTUFII family patents
2. Abilify Maintena Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage
ABILIFY MAINTENA KIT family patents
3. Abilify Mycite Kit patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9577864 | OTSUKA | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
Oct, 2033
(9 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a logic circuit to stabilize battery v...
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
4. Aczone patent expiration
ACZONE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517219 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| US9161926 | ALMIRALL | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| US11273132 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Feb 24, 2019 |
| New Patient Population(NPP) | Sep 10, 2022 |
Drugs and Companies using DAPSONE ingredient
Market Authorisation Date: 24 February, 2016
Treatment: Topical treatment of acne vulgaris
Dosage: GEL
How can I launch a generic of ACZONE before it's drug patent expiration?
More Information on Dosage
ACZONE family patents
5. Admelog Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ADMELOG SOLOSTAR family patents
6. Agamree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690853 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Treatment: Treatment of duchenne muscular dystrophy
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
7. Aklief patent expiration
AKLIEF's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(8 years from now) | |
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Treatment of acne vulgaris; Topical treatment of acne vulgaris
Dosage: CREAM
More Information on Dosage
AKLIEF family patents
8. Alkindi Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675559 | ETON | Treatment of adrenal insufficiency |
Jan, 2033
(8 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE
More Information on Dosage
ALKINDI SPRINKLE family patents
9. Antara (micronized) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(8 years from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treating severe hypertriglyceridemia
Dosage: CAPSULE
How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage
ANTARA (MICRONIZED) family patents
10. Apidra Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
APIDRA SOLOSTAR family patents
11. Aristada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11097006 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(9 years from now) | |
| US9193685 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ARISTADA family patents
12. Arymo Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9044402 | ZYLA | Abuse-deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(8 years from now) | |
| US9549899 | ZYLA | Abuse deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(8 years from now) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 09 January, 2017
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ARYMO ER before it's drug patent expiration?
More Information on Dosage
ARYMO ER family patents
13. Austedo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: A method of treating huntington's chorea
Dosage: TABLET
How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage
AUSTEDO family patents
14. Austedo Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of tardive dyskinesia
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
AUSTEDO XR family patents
15. Auvelity patent expiration
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8569328 | AXSOME | Compositions and methods comprising tilidine or related compounds and dextromethorphan |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage
AUVELITY family patents
16. Balversa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage
BALVERSA family patents
17. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
BAXDELA family patents
18. Belsomra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(8 years from now) | |
| US11980623 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
| M(M-253) | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Treatment: NA
Dosage: TABLET
More Information on Dosage
BELSOMRA family patents
19. Belviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd
Dosage: TABLET
How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage
BELVIQ family patents
20. Belviq Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage
BELVIQ XR family patents
21. Bendeka patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10052385 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9144568 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9000021 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
| US9597397 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9572887 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9597399 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9597398 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9034908 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9579384 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with...
Dosage: SOLUTION
How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage
BENDEKA family patents
22. Biktarvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9216996 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
Dec, 2033
(9 years from now) | |
| US9732092 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
Dec, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 18, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2023 |
| M(M-82) | Feb 24, 2024 |
| Orphan Drug Exclusivity(ODE-256) | Jun 18, 2026 |
| New Indication(I-942) | Feb 23, 2027 |
| M(M-305) | Apr 24, 2027 |
| Orphan Drug Exclusivity(ODE-378) | Oct 07, 2028 |
| Orphan Drug Exclusivity(ODE-468) | Feb 23, 2031 |
NCE-1 date: 07 February, 2022
Market Authorisation Date: 07 October, 2021
Treatment: NA
Dosage: TABLET
How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage
BIKTARVY family patents
23. Bonjesta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089489 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
| US9375404 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
| US9937132 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
| US9526703 | DUCHESNAY | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 November, 2016
Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of BONJESTA before it's drug patent expiration?
More Information on Dosage
BONJESTA family patents
24. Braftovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474754 | ARRAY BIOPHARMA INC | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-826) | Apr 08, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-ap...
Dosage: CAPSULE
How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage
BRAFTOVI family patents
25. Byfavo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 06 October, 2024
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER
More Information on Dosage
BYFAVO family patents
26. Cabometyx patent expiration
CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724342 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
27. Caplyta patent expiration
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48839 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of schizophrenia
Dosage: CAPSULE
More Information on Dosage
CAPLYTA family patents
28. Carnexiv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | LUNDBECK PHARMS LLC | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
| Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
CARNEXIV family patents
29. Cequa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980839 | SUN PHARM | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
Aug, 2033
(9 years from now) | |
| US10441630 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(9 years from now) | |
| US9937225 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(9 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION
More Information on Dosage
CEQUA family patents
30. Clorotekal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504666 | B BRAUN MEDICAL INC | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2020 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 September, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
CLOROTEKAL family patents
31. Complera patent expiration
COMPLERA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857102 | GILEAD SCIENCES INC | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Dec 13, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage
COMPLERA family patents
32. Contrave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10403170 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(8 years from now) | |
| US11139056 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(8 years from now) | |
| US9633575 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage
CONTRAVE family patents
33. Cytalux patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9789208 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9333270 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9341629 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US10881747 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9061057 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9254341 | ON TARGET LABS | Methods of manufacture of pteroyl-amino acid-fluorescent dyes |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-905) | Dec 16, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2026 |
| Orphan Drug Exclusivity(ODE-390) | Nov 29, 2028 |
Drugs and Companies using PAFOLACIANINE SODIUM ingredient
NCE-1 date: 29 November, 2025
Market Authorisation Date: 29 November, 2021
Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions
Dosage: SOLUTION
More Information on Dosage
CYTALUX family patents
34. Daptomycin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9655946 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
| US10357535 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 21 June, 2021
Treatment: Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the f...
Dosage: POWDER
More Information on Dosage
DAPTOMYCIN family patents
35. Descovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 28, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: NA
Dosage: TABLET
How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage
DESCOVY family patents
36. Docetaxel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763880 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US8940786 | SHILPA | Non-aqueous taxane nanodispersion formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US9308195 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy; Method of administering an ethanol-free taxane liquid nanodispe...
Dosage: INJECTABLE
More Information on Dosage
DOCETAXEL family patents
37. Empaveli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-288) | Feb 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
| Orphan Drug Exclusivity(ODE-351) | May 14, 2028 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administrat...
Dosage: SOLUTION
More Information on Dosage
EMPAVELI family patents
38. Entresto patent expiration
ENTRESTO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11135192 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| US9517226 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| US9937143 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| M(M-82) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: Treatment of heart failure with preserved ejection fraction
Dosage: TABLET
How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage
ENTRESTO family patents
39. Epanova patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9050309 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9050308 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| US10117844 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2019 |
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
NCE-1 date: 05 May, 2018
Market Authorisation Date: 05 May, 2014
Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet
Dosage: CAPSULE
More Information on Dosage
EPANOVA family patents
40. Epclusa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-277) | Apr 27, 2025 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: NA
Dosage: PELLETS; TABLET
More Information on Dosage
EPCLUSA family patents
41. Erleada patent expiration
ERLEADA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49353 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prosta...
Dosage: TABLET
How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage
ERLEADA family patents
42. Esbriet patent expiration
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder
Dosage: TABLET
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
43. Esmolol Hydrochloride Double Strength In Plastic Container patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8829054 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
| US8835505 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 07 April, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER family patents
44. Esmolol Hydrochloride In Plastic Container patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835505 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
| US8829054 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 07 April, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER family patents
45. Evomela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | ACROTECH BIOPHARMA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
| Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER
How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage
EVOMELA family patents
46. Evrysdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| M(M-270) | Oct 03, 2026 |
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: NA
Dosage: FOR SOLUTION
More Information on Dosage
EVRYSDI family patents
47. Eysuvis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US11219596 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US10857096 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US11596599 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US11872318 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US10993908 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US10945948 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US10940108 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US10646436 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for delivering a composition to a mucus membrane; A method for treating dry eye in a patient; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the ey...
Dosage: SUSPENSION/DROPS
More Information on Dosage
EYSUVIS family patents
48. Fetroja patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
Dosage: POWDER
More Information on Dosage
FETROJA family patents
49. Fintepla patent expiration
FINTEPLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478441 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(8 years from now) | |
| US10478442 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(8 years from now) | |
| US9603814 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(8 years from now) | |
| US9610260 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(8 years from now) | |
| US9549909 | UCB INC | Method for the treatment of dravet syndrome |
May, 2033
(8 years from now) | |
| US9603815 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(8 years from now) | |
|
US10478441 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9603815 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9549909 (Pediatric) | UCB INC | Method for the treatment of dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9610260 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US9603814 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US10478442 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 25, 2023 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated...
Dosage: SOLUTION
How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage
FINTEPLA family patents
50. Genvoya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage
GENVOYA family patents
51. Givlaari patent expiration
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
52. Harvoni patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9393256 (Pediatric) | GILEAD SCIENCES INC | Methods for treating HCV |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: NA
Dosage: PELLETS; TABLET
More Information on Dosage
HARVONI family patents
53. Hepzato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195334 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-438) | Aug 14, 2030 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 August, 2023
Treatment: NA
Dosage: POWDER
More Information on Dosage
HEPZATO family patents
54. Hetlioz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US8785492 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11826339 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11918557 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11918556 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of non-24 hour sleep-wake disorder by avoiding the admin...
Dosage: CAPSULE
How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage
HETLIOZ family patents
55. Hetlioz Lq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11826339 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11918557 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11918556 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome...
Dosage: SUSPENSION
More Information on Dosage
HETLIOZ LQ family patents
56. Ibsrela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
IBSRELA family patents
57. Iclusig patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11384086 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| US9493470 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| US11192897 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11192895 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE-35) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| New Indication(I-849) | Dec 18, 2023 |
| New Indication(I-934) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-472) | Mar 19, 2031 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 18 December, 2020
Treatment: A method for treating chronic myeloid leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia
Dosage: TABLET
How can I launch a generic of ICLUSIG before it's drug patent expiration?
More Information on Dosage
ICLUSIG family patents
58. Idhifa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512107 | BRISTOL MYERS SQUIBB | Therapeutically active compositions and their methods of use |
Jan, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294215 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET
More Information on Dosage
IDHIFA family patents
59. Imbruvica patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9725455 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10106548 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10125140 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9296753 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10752634 | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10961251 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10294232 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10294231 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9713617 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9540382 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(9 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| M(M-14) | Aug 04, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 20 December, 2017
Treatment: Treatment of mantle cell lymphoma
Dosage: CAPSULE; TABLET; SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
60. Imvexxy patent expiration
IMVEXXY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888516 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(8 years from now) | |
| US10568891 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(8 years from now) | |
| US10471072 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(8 years from now) | |
| US11065197 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(8 years from now) | |
| US11123283 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(8 years from now) | |
| US10668082 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(8 years from now) | |
| US11116717 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(8 years from now) | |
| US9180091 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(9 years from now) | |
| US10258630 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| US10398708 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2021 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia; Treatment of moderate to severe dyspareunia
Dosage: INSERT
How can I launch a generic of IMVEXXY before it's drug patent expiration?
More Information on Dosage
IMVEXXY family patents
61. Infugem patent expiration
INFUGEM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9241948 | SUN PHARM | Ready to be infused gemcetabine solution |
Jul, 2033
(8 years from now) | |
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 July, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
INFUGEM family patents
62. Inveltys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US11219597 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US10864219 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US11872318 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US10646437 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(8 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 22, 2021 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method of treating postoperative inflammation following ocular surgery; A method for treating ocular inflammation; A method for treating in...
Dosage: SUSPENSION/DROPS
More Information on Dosage
INVELTYS family patents
63. Ionsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9095706 | THE MEDICINES CO | Self-test for analgesic product |
Feb, 2033
(8 years from now) | |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
IONSYS family patents
64. Jentadueto Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555001 | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Mar, 2033
(8 years from now) | |
|
US9555001 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination wit...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
65. Kalydeco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752106 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 03 May, 2023
Treatment: Treatment of cf in a patient age 1 month to <6 years who has at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition r...
Dosage: GRANULE
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
66. Kengreal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Treatment: Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading d...
Dosage: POWDER
How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage
KENGREAL family patents
67. Korlym patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500216 | CORCEPT THERAP | Optimizing mifepristone absorption |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET
How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage
KORLYM family patents
68. Kuvan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9216178 (Pediatric) | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
May, 2033
(8 years from now) | |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: NA
Dosage: POWDER
How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage
KUVAN family patents
69. Kyprolis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | ONYX PHARMS AMGEN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-723) | Jan 21, 2019 |
| New Indication(I-722) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: NA
Dosage: POWDER
How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage
KYPROLIS family patents
70. Kyzatrex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11617758 | MARIUS PHARMS LLC | Emulsion formulations |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE
More Information on Dosage
KYZATREX family patents
71. Lantus Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LANTUS SOLOSTAR family patents
72. Liletta patent expiration
LILETTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12004992 | MEDICINES360 | Kits for intrauterine systems and IUD insertion devices |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090186 | MEDICINES360 | Methods for using intrauterine systems and IUD insertion devices |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 26, 2018 |
| New Indication(I-917) | Jun 29, 2026 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: A method for prevention of pregnancy
Dosage: SYSTEM
More Information on Dosage
LILETTA family patents
73. Linzess patent expiration
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
74. Liposyn Iii 30% patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | HOSPIRA | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
Drugs and Companies using SOYBEAN OIL ingredient
Market Authorisation Date: 13 January, 1998
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LIPOSYN III 30% family patents
75. Lodoco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026901 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US11026900 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US11944594 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US11944595 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US11026899 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US9744144 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Nov, 2033
(9 years from now) | |
| US10842762 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Nov, 2033
(9 years from now) | |
| US10265281 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US10206891 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Nov, 2033
(9 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 16 June, 2023
Treatment: A method for treating and/or reducing the risk of acute myocardial infarction; A method for treating and/or reducing the risk of a cardiovascular event; Method for reducing a risk of at least one card...
Dosage: TABLET
More Information on Dosage
LODOCO family patents
76. Lokelma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10695365 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| US8877255 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| US9913860 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-261) | Apr 24, 2023 |
| New Chemical Entity Exclusivity(NCE) | May 18, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 18 May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION
How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage
LOKELMA family patents
77. Lonhala Magnair Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604018 | SUMITOMO PHARMA AM | Aerosol therapy device |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
LONHALA MAGNAIR KIT family patents
78. Lorbrena patent expiration
Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 02, 2023 |
| New Indication(I-847) | Mar 03, 2024 |
| Orphan Drug Exclusivity(ODE-218) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-219) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-217) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-349) | Mar 03, 2028 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: 02 November, 2022
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
LORBRENA family patents
79. Luzu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(9 years from now) | |
| US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(9 years from now) | |
| US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2018 |
| New Patient Population(NPP) | Feb 20, 2021 |
Drugs and Companies using LULICONAZOLE ingredient
NCE-1 date: 14 November, 2017
Market Authorisation Date: 14 November, 2013
Treatment: Treatment of fungal infections
Dosage: CREAM
More Information on Dosage
LUZU family patents
80. Lytgobi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
| Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET
More Information on Dosage
LYTGOBI family patents
81. Mekinist patent expiration
MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-908) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement o...
Dosage: TABLET
More Information on Dosage
MEKINIST family patents
82. Mektovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Treatment of melanoma with a braf mutation; Method of treating melanoma
Dosage: TABLET
How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage
MEKTOVI family patents
83. Miebo patent expiration
MIEBO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576154 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| US10058615 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| US10449164 | BAUSCH AND LOMB INC | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| US10369117 | BAUSCH AND LOMB INC | Compositions comprising mixtures of semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
More Information on Dosage
MIEBO family patents
84. Mitigare patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789108 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US8927607 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9675613 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9555029 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9399036 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: Method of using colchicine for the prophylaxis of gout flares
Dosage: CAPSULE
How can I launch a generic of MITIGARE before it's drug patent expiration?
More Information on Dosage
MITIGARE family patents
85. Myfembree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11795178 | MYOVANT SCIENCES | Compositions of thienopyrimidine derivatives |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2024 |
| New Indication(I-898) | Aug 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
MYFEMBREE family patents
86. Naftin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10166205 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10695303 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10729667 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US9161914 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US8778365 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10166206 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2016 |
Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 June, 2013
Treatment: Treatment of fungal infections
Dosage: GEL
How can I launch a generic of NAFTIN before it's drug patent expiration?
More Information on Dosage
NAFTIN family patents
87. Natroba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9895388 | PARAPRO LLC | Methods and compositions useful for controlling cutaneous mites |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2016 |
| M(M-152) | Nov 30, 2017 |
| New Indication(I-858) | Apr 28, 2024 |
Drugs and Companies using SPINOSAD ingredient
NCE-1 date: 18 January, 2015
Market Authorisation Date: 18 January, 2011
Treatment: The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites ...
Dosage: SUSPENSION
More Information on Dosage
NATROBA family patents
88. Noxafil patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
89. Nubeqa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET
More Information on Dosage
NUBEQA family patents
90. Nurtec Odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8759372 | PFIZER | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-865) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING
More Information on Dosage
NURTEC ODT family patents
91. Ocaliva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(8 years from now) | |
| US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-119) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Treatment of primary biliary cholangitis (pbc)
Dosage: TABLET
How can I launch a generic of OCALIVA before it's drug patent expiration?
More Information on Dosage
OCALIVA family patents
92. Odefsey patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-207) | Aug 21, 2020 |
| M(M-206) | Aug 21, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage
ODEFSEY family patents
93. Omidria patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066856 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| US9855246 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| US9486406 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2017 |
| New Patient Population(NPP) | Dec 08, 2020 |
| Pediatric Exclusivity(PED) | Jun 08, 2021 |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of OMIDRIA before it's drug patent expiration?
More Information on Dosage
OMIDRIA family patents
94. Onivyde patent expiration
ONIVYDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9452162 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(8 years from now) | |
| US11369597 | IPSEN | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(8 years from now) | |
| US10980795 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(8 years from now) | |
| US9364473 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(8 years from now) | |
| US9339497 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(8 years from now) | |
| US9717724 | IPSEN | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(8 years from now) | |
| US9492442 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has prog...
Dosage: INJECTABLE, LIPOSOMAL
More Information on Dosage
ONIVYDE family patents
95. Onzetra Xsail patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(9 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of delivering sumatriptan to a nasal cavity
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
96. Opfolda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278599 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Mar, 2033
(8 years from now) | |
| US10512677 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE
More Information on Dosage
OPFOLDA family patents
97. Orfadin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9301932 | SWEDISH ORPHAN | Liquid pharmaceutical composition comprising nitisinone |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-169) | Sep 01, 2020 |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 22 April, 2016
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: SUSPENSION
More Information on Dosage
ORFADIN family patents
98. Orgovyx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11795178 | SUMITOMO PHARMA | Compositions of thienopyrimidine derivatives |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
ORGOVYX family patents
99. Oxbryta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9018210 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-281) | Nov 25, 2026 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 14 October, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION; TABLET
More Information on Dosage
OXBRYTA family patents
100. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents
101. Pemazyre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-899) | Aug 26, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement
Dosage: TABLET
More Information on Dosage
PEMAZYRE family patents
102. Phenylephrine Hydrochloride patent expiration
PHENYLEPHRINE HYDROCHLORIDE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859623 | PARAGON BIOTECK | Methods and compositions of stable phenylephrine formulations |
Nov, 2033
(9 years from now) | |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 March, 2013
Treatment: Dilation of the pupil
Dosage: SOLUTION/DROPS
More Information on Dosage
PHENYLEPHRINE HYDROCHLORIDE family patents
103. Phexxi patent expiration
Can you believe PHEXXI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11439610 | EVOFEM INC | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
Mar, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337989 | EVOFEM INC | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
Mar, 2033
(8 years from now) | |
| US11992472 | EVOFEM INC | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
Mar, 2033
(8 years from now) | |
| US10568855 | EVOFEM INC | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 22, 2023 |
Drugs and Companies using CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE ingredient
Market Authorisation Date: 22 May, 2020
Treatment: Prevention of pregnancy
Dosage: GEL
How can I launch a generic of PHEXXI before it's drug patent expiration?
More Information on Dosage
PHEXXI family patents
104. Picato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
| M(M-169) | Nov 19, 2018 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Treatment: Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate
Dosage: GEL
How can I launch a generic of PICATO before it's drug patent expiration?
More Information on Dosage
PICATO family patents
105. Piqray patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| New Indication(I-937) | Jan 18, 2027 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET
More Information on Dosage
PIQRAY family patents
106. Plenvu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9326969 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US8999313 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US10016504 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US9707297 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US10918723 | SALIX | Colon cleansing compositions and methods of use |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 04, 2021 |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION
How can I launch a generic of PLENVU before it's drug patent expiration?
More Information on Dosage
PLENVU family patents
107. Prevymis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
PREVYMIS family patents
108. Prolensa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Dosage: SOLUTION/DROPS
How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage
PROLENSA family patents
109. Pyrukynd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11793806 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
| Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency
Dosage: TABLET
More Information on Dosage
PYRUKYND family patents
110. Qbrexza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10548875 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10543192 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US9006462 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US10004717 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US8859610 | JOURNEY | Crystalline glycopyrrolate tosylate |
Feb, 2033
(8 years from now) | |
| US9259414 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2021 |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH
How can I launch a generic of QBREXZA before it's drug patent expiration?
More Information on Dosage
QBREXZA family patents
111. Qelbree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
QELBREE family patents
112. Qudexy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8889190 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US9101545 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US8652527 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US9555005 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US10363224 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Treatment of seizures
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of QUDEXY XR before it's drug patent expiration?
More Information on Dosage
QUDEXY XR family patents
113. Quillichew Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857143 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9844544 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9295642 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11103494 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US8999386 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11103495 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11633389 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9545399 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 04, 2018 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 December, 2015
Treatment: A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with a th...
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE
How can I launch a generic of QUILLICHEW ER before it's drug patent expiration?
More Information on Dosage
QUILLICHEW ER family patents
114. Qulipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
QULIPTA family patents
115. Quviviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 07 April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET
More Information on Dosage
QUVIVIQ family patents
116. Recarbrio patent expiration
Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 16 July, 2028
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)
Dosage: POWDER
More Information on Dosage
RECARBRIO family patents
117. Relyvrio patent expiration
RELYVRIO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2027 |
| Orphan Drug Exclusivity(ODE-411) | Sep 29, 2029 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: 29 September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION
More Information on Dosage
RELYVRIO family patents
118. Rexulti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10307419 (Pediatric) | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| Pediatric Exclusivity(PED) | Nov 10, 2026 |
| M(M-14) | May 08, 2027 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 10 November, 2025
Market Authorisation Date: 10 July, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage
REXULTI family patents
119. Rezdiffra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9266861 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
| US11564926 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376517 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
| US11986481 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents
120. Rezurock patent expiration
REZUROCK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus hold disease; For the treatment of chronic graft versus host disease
Dosage: TABLET
More Information on Dosage
REZUROCK family patents
121. Rezzayo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9526835 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(8 years from now) | |
| US10702573 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER
More Information on Dosage
REZZAYO family patents
122. Rinvoq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47221 | ABBVIE | Tricyclic compounds |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Indication(I-880) | Dec 14, 2024 |
| New Indication(I-883) | Jan 14, 2025 |
| New Indication(I-886) | Mar 16, 2025 |
| New Indication(I-888) | Apr 29, 2025 |
| New Indication(I-919) | May 18, 2026 |
| New Patient Population(NPP) | Apr 24, 2027 |
| New Indication(I-946) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RINVOQ family patents
123. Rinvoq Lq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47221 | ABBVIE | Tricyclic compounds |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Product(NP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 26 April, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RINVOQ LQ family patents
124. Roszet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376470 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(8 years from now) | |
| US9763885 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(8 years from now) | |
Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 23 March, 2021
Treatment: Treatment of hyperlipidemia
Dosage: TABLET
More Information on Dosage
ROSZET family patents
125. Rozlytrek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of ros1-positive non-small cell lung cancer
Dosage: CAPSULE
More Information on Dosage
ROZLYTREK family patents
126. Rybelsus patent expiration
RYBELSUS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759502 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US11759501 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US11759503 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
RYBELSUS family patents
127. Rytelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9375485 | GERON | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-482) | Jun 06, 2031 |
Drugs and Companies using IMETELSTAT SODIUM ingredient
Market Authorisation Date: 06 June, 2024
Treatment: Treatment of patients with myelodysplastic syndromes (mds) with transfusion-dependent anemia
Dosage: POWDER
More Information on Dosage
RYTELO family patents
128. Ryzodeg 70/30 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884094 | NOVO | Method of treating diabetes mellitus |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: Method of improving glycemic control in patients with diabetes mellitus by administering a mixture of insulin degludec and insulin aspart during or around the time of the largest meal of the day
Dosage: SOLUTION
More Information on Dosage
RYZODEG 70/30 family patents
129. Scemblix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
| ODE*(ODE*) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET
More Information on Dosage
SCEMBLIX family patents
130. Secuado patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022445 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US10583121 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US11123305 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US9687474 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US10814002 | HISAMITSU | Patch and method for producing the same |
Jul, 2033
(9 years from now) | |
| US11813364 | HISAMITSU | Patch |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2022 |
Drugs and Companies using ASENAPINE ingredient
Market Authorisation Date: 11 October, 2019
Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch
Dosage: SYSTEM
More Information on Dosage
SECUADO family patents
131. Sesquient patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | LUPIN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
Drugs and Companies using FOSPHENYTOIN SODIUM ingredient
Market Authorisation Date: 05 November, 2020
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SESQUIENT family patents
132. Seysara patent expiration
Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 01, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 01 October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydroch...
Dosage: TABLET
More Information on Dosage
SEYSARA family patents
133. Skyclarys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9701709 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(8 years from now) | |
| US8993640 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2028 |
| Orphan Drug Exclusivity(ODE-427) | Feb 28, 2030 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 28 February, 2027
Market Authorisation Date: 28 February, 2023
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
SKYCLARYS family patents
134. Soaanz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10154963 | SARFE PHARMS | Controlled-release formulations comprising Torsemide |
Oct, 2033
(9 years from now) | |
Drugs and Companies using TORSEMIDE ingredient
Market Authorisation Date: 14 June, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
SOAANZ family patents
135. Soliqua 100/33 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
136. Sotyktu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(9 years from now) | |
| US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Dosage: TABLET
More Information on Dosage
SOTYKTU family patents
137. Spravato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-840) | Jul 31, 2023 |
| NCE*(NCE*) | Mar 05, 2024 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant
Dosage: SPRAY
How can I launch a generic of SPRAVATO before it's drug patent expiration?
More Information on Dosage
SPRAVATO family patents
138. Stribild patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 27, 2015 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Indication(I-704) | Dec 17, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of STRIBILD before it's drug patent expiration?
More Information on Dosage
STRIBILD family patents
139. Syfovre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan
Dosage: SOLUTION
More Information on Dosage
SYFOVRE family patents
140. Symdeko (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(8 years from now) | |
| US10058546 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof |
Jul, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or heterozygous for the f508del mutation and a second mutation that is responsive ...
Dosage: TABLET
More Information on Dosage
SYMDEKO (COPACKAGED) family patents
141. Symproic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
SYMPROIC family patents
142. Tafinlar patent expiration
TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-908) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement o...
Dosage: CAPSULE
More Information on Dosage
TAFINLAR family patents
143. Tazverik patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2; Method of treating epithelioid sarcoma; Method of treatin...
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
144. Tibsovo patent expiration
Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(8 years from now) | |
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11667673 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-816) | May 02, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-893) | May 25, 2025 |
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating a cancer characterized by an idh1 mutation wherein the cancer is relapsed or refractory myelodysplastic syndromes; A method of treating previously treated, locally advanced or met...
Dosage: TABLET
How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage
TIBSOVO family patents
145. Tigecycline patent expiration
Can you believe TIGECYCLINE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855355 | AMNEAL | Method and device for plasma-treating hollow bodies |
Apr, 2033
(8 years from now) | |
| US9855335 | AMNEAL | Tigecycline composition for injection |
Apr, 2033
(8 years from now) | |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 02 August, 2018
Treatment: NA
Dosage: POWDER
More Information on Dosage
TIGECYCLINE family patents
146. Tolsura patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921374 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(8 years from now) | |
| US10463740 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(8 years from now) | |
| US9272046 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(8 years from now) | |
| US10806792 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(8 years from now) | |
| US9713642 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(8 years from now) | |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 December, 2018
Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis
Dosage: CAPSULE
More Information on Dosage
TOLSURA family patents
147. Trikafta (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US11752106 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cf in patients aged 2 to <6 years who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data comprising administering a composition ac...
Dosage: GRANULES; TABLET
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
148. Trudhesa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940278 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Jan, 2033
(8 years from now) | |
| US9919117 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 02, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED
More Information on Dosage
TRUDHESA family patents
149. Truqap patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9487525 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039766 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET
More Information on Dosage
TRUQAP family patents
150. Tukysa patent expiration
TUKYSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504370 | SEAGEN | Treatment of brain cancer |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET
More Information on Dosage
TUKYSA family patents
151. Turalio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
| ODE*(ODE*) | Aug 02, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE
More Information on Dosage
TURALIO family patents
152. Tybost patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Aug 22, 2022 |
| Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of TYBOST before it's drug patent expiration?
More Information on Dosage
TYBOST family patents
153. Ubrelvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
154. Ukoniq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 05, 2026 |
| Orphan Drug Exclusivity(ODE-343) | Feb 05, 2028 |
| Orphan Drug Exclusivity(ODE-344) | Feb 05, 2028 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 05 February, 2025
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one pri...
Dosage: TABLET
More Information on Dosage
UKONIQ family patents
155. Ultravate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962028 | MICAL PHARMS | Topical steroid composition and method |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 06, 2018 |
| New Patient Population(NPP) | Aug 31, 2023 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2015
Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis
Dosage: LOTION
How can I launch a generic of ULTRAVATE before it's drug patent expiration?
More Information on Dosage
ULTRAVATE family patents
156. Uzedy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9023897 | TEVA | Biodegradable drug delivery compositions |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2026 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
UZEDY family patents
157. Vanflyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675549 | DAIICHI SANKYO INC | Tablet containing composite with cyclodextrin |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
VANFLYTA family patents
158. Vascepa patent expiration
VASCEPA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10555925 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US11116742 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US10894028 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10786478 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US10792270 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10576054 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10668042 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US10568861 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10383840 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US11369582 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US9603826 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9610272 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9918954 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10278935 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US10278937 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US11298333 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| US10555924 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
| US10278936 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9693986 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9693985 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9623001 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US9693984 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
| US11000499 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the ri...
Dosage: CAPSULE
How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage
VASCEPA family patents
159. Veltassa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER
How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage
VELTASSA family patents
160. Vemlidy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 11, 2019 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-255) | Feb 04, 2023 |
| M(M-266) | Aug 22, 2023 |
| New Patient Population(NPP) | Oct 17, 2025 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of VEMLIDY before it's drug patent expiration?
More Information on Dosage
VEMLIDY family patents
161. Venclexta patent expiration
VENCLEXTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11413282 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US9539251 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatmen...
Dosage: TABLET
How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage
VENCLEXTA family patents
162. Viberzi patent expiration
VIBERZI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food
Dosage: TABLET
How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage
VIBERZI family patents
163. Victoza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9265893 (Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
164. Viekira Pak (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629841 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
| US10201542 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-163) | Apr 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using dasabuvir
Dosage: TABLET
More Information on Dosage
VIEKIRA PAK (COPACKAGED) family patents
165. Vijoice patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| Orphan Drug Exclusivity(ODE-396) | Apr 05, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET; GRANULES
More Information on Dosage
VIJOICE family patents
166. Vivjoa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 27 April, 2031
Market Authorisation Date: 26 April, 2022
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
Dosage: CAPSULE
More Information on Dosage
VIVJOA family patents
167. Vivlodex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9526734 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 22 October, 2015
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of VIVLODEX before it's drug patent expiration?
More Information on Dosage
VIVLODEX family patents
168. Vosevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
VOSEVI family patents
169. Vumerity patent expiration
VUMERITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
| US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Market Authorisation Date: 29 October, 2019
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of VUMERITY before it's drug patent expiration?
More Information on Dosage
VUMERITY family patents
170. Vyleesi (autoinjector) patent expiration
VYLEESI (AUTOINJECTOR)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10286034 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| US9700592 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| US9352013 | COSETTE | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd)
Dosage: SOLUTION
More Information on Dosage
VYLEESI (AUTOINJECTOR) family patents
171. Wegovy patent expiration
WEGOVY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Jun 04, 2024 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule
Dosage: SOLUTION
How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage
WEGOVY family patents
172. Xacduro (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9309245 | ENTASIS THERAP | Beta-lactamase inhibitor compounds |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9623014 | ENTASIS THERAP | β-lactamase inhibitor compounds |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2033 |
Drugs and Companies using DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM ingredient
NCE-1 date: 23 May, 2032
Market Authorisation Date: 23 May, 2023
Treatment: Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp)
Dosage: POWDER
More Information on Dosage
XACDURO (COPACKAGED) family patents
173. Xaracoll patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11746141 | INNOCOLL PHARMS | Modified collagen |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 28, 2023 |
Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2020
Treatment: NA
Dosage: IMPLANT
More Information on Dosage
XARACOLL family patents
174. Xatmep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259427 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10231927 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US9855215 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US11969503 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10610485 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US11116724 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-137) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE-138) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 25, 2024 |
Drugs and Companies using METHOTREXATE SODIUM ingredient
Market Authorisation Date: 25 April, 2017
Treatment: Treatment of juvenile rheumatoid arthritis; A method for treating acute lymphoblastic leukemia
Dosage: SOLUTION
More Information on Dosage
XATMEP family patents
175. Xelstrym patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9456993 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| US9474722 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine
Dosage: SYSTEM
More Information on Dosage
XELSTRYM family patents
176. Xhance patent expiration
XHANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033696 | OPTINOSE US INC | Nasal delivery devices |
May, 2033
(8 years from now) | |
| US10179216 | OPTINOSE US INC | Nasal delivery devices |
Jul, 2033
(8 years from now) | |
| US10478574 | OPTINOSE US INC | Nasal administration |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
177. Xiidra patent expiration
Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9085553 | BAUSCH AND LOMB INC | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(9 years from now) | |
| US11058677 | BAUSCH AND LOMB INC | LFA-1 inhibitor formulations |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage
XIIDRA family patents
178. Xipere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636332 | BAUSCH AND LOMB INC | Methods and devices for the treatment of ocular diseases in human subjects |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION
More Information on Dosage
XIPERE family patents
179. Xphozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 17 October, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
XPHOZAH family patents
180. Xpovio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8999996 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-837) | Jun 22, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2024 |
| ODE*(ODE*) | Jun 22, 2027 |
| Orphan Drug Exclusivity(ODE-257) | Jul 03, 2026 |
| Orphan Drug Exclusivity(ODE-310) | Jun 22, 2027 |
| Orphan Drug Exclusivity(ODE-346) | Dec 18, 2027 |
Drugs and Companies using SELINEXOR ingredient
NCE-1 date: 04 July, 2023
Market Authorisation Date: 03 July, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
XPOVIO family patents
181. Xtandi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11839689 | ASTELLAS | Formulations of enzalutamide |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-786) | Jul 13, 2021 |
| New Indication(I-808) | Dec 16, 2022 |
| New Indication(I-926) | Nov 17, 2026 |
Drugs and Companies using ENZALUTAMIDE ingredient
Market Authorisation Date: 04 August, 2020
Treatment: NA
Dosage: TABLET
How can I launch a generic of XTANDI before it's drug patent expiration?
More Information on Dosage
XTANDI family patents
182. Xtoro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504691 | FONSECA BIOSCIENCES | Finafloxacin suspension compositions |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
| Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS
More Information on Dosage
XTORO family patents
183. Xyosted (autoinjector) patent expiration
Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844804 | ANTARES PHARMA INC | Administration of testosterone compositions |
Jun, 2033
(8 years from now) | |
| US10821072 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Jun, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION
More Information on Dosage
XYOSTED (AUTOINJECTOR) family patents
184. Xyrem patent expiration
XYREM's oppositions filed in EPO
XYREM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10864181 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9486426 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10213400 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US11986446 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US11253494 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
|
US10864181 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10213400 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9050302 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US11253494 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US8772306 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9486426 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of reducing adverse effects in...
Dosage: SOLUTION
How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage
XYREM family patents
185. Xywav patent expiration
XYWAV's oppositions filed in EPO
XYWAV IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132107 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US8591922 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US11554102 | JAZZ | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US10675258 | JAZZ | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US8901173 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US10195168 | JAZZ | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US11986446 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9050302 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10213400 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9486426 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US8772306 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US11253494 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10864181 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
|
US11253494 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9050302 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9486426 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10213400 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US8772306 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10864181 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 21, 2023 |
| New Indication(I-870) | Aug 12, 2024 |
| Orphan Drug Exclusivity(ODE-361) | Jul 21, 2027 |
| Orphan Drug Exclusivity(ODE-231) | Jul 21, 2027 |
| Orphan Drug Exclusivity(ODE-369) | Aug 12, 2028 |
Market Authorisation Date: 21 July, 2020
Treatment: Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb; Method of tr...
Dosage: SOLUTION
How can I launch a generic of XYWAV before it's drug patent expiration?
More Information on Dosage
XYWAV family patents
186. Yosprala patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987231 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Jan, 2033
(8 years from now) | |
| US9539214 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 14, 2019 |
Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient
Market Authorisation Date: 14 September, 2016
Treatment: For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers; Treatment or secondary prevention of cardiovascular disease, ...
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of YOSPRALA before it's drug patent expiration?
More Information on Dosage
YOSPRALA family patents
187. Zerviate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9254286 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 30, 2020 |
| Pediatric Exclusivity(PED) | Nov 30, 2020 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: NA
Dosage: SOLUTION/DROPS
More Information on Dosage
ZERVIATE family patents
188. Zohydro Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421200 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9610286 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9265760 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9339499 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9326982 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10028946 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9333201 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10322120 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10456393 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9433619 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10722511 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 25, 2016 |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 25 October, 2013
Treatment: Treatment of pain in patients with hepatic impairment
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of ZOHYDRO ER before it's drug patent expiration?
More Information on Dosage
ZOHYDRO ER family patents
189. Zulresso patent expiration
ZULRESSO's oppositions filed in EPO
Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10322139 | SAGE THERAP | Neuroactive steroid formulations and methods of treating CNS disorders |
Jan, 2033
(8 years from now) | |
| US10251894 | SAGE THERAP | Anticonvulsant activity of steroids |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| New Patient Population(NPP) | Jun 16, 2025 |
Drugs and Companies using BREXANOLONE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Method of treating postpartum depression
Dosage: SOLUTION
More Information on Dosage
ZULRESSO family patents
190. Zydelig patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: For the treatment of patients with cll, fl, or sll
Dosage: TABLET
How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage
ZYDELIG family patents
List of large molecules
1. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9085618 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | |
| US9334319 | ABBVIE INC. | Low acidic species compositions |
Mar, 2033
(8 years from now) | |
| US9290568 | ABBVIE INC. | Methods to control protein heterogeneity |
Mar, 2033
(8 years from now) | |
| US9708400 | ABBVIE INC. | Methods to modulate lysine variant distribution |
Mar, 2033
(8 years from now) | |
| US9181572 | ABBVIE INC. | Methods to modulate lysine variant distribution |
Mar, 2033
(8 years from now) | |
| US9181337 | ABBVIE INC. | Modulated lysine variant species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | |
| US9499616 | ABBVIE INC. | Modulated lysine variant species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | |
| US9359434 | ABBVIE INC. | Cell culture methods to reduce acidic species |
Mar, 2033
(8 years from now) | |
| US9346879 | ABBVIE INC. | Protein purification methods to reduce acidic species |
Mar, 2033
(8 years from now) | |
| US9315574 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Apr, 2033
(8 years from now) | |
| US9150645 | ABBVIE INC. | Cell culture methods to reduce acidic species |
May, 2033
(8 years from now) | |
| US9266949 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
May, 2033
(8 years from now) |
Ingredients: ADALIMUMAB
2. List of Evenity large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8017120 | NA | Method for inhibiting bone resorption |
Apr, 2033
(8 years from now) |
Ingredients: ROMOSOZUMAB-AQQG
3. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9562252 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
May, 2033
(8 years from now) |
Ingredients: NATALIZUMAB
4. List of Lucentis large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10421984 | GENENTECH, INC. | Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele |
Sep, 2033
(9 years from now) |
Ingredients: RANIBIZUMAB
5. List of Emgality large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9073991 | NA | NA |
Sep, 2033
(9 years from now) |
Ingredients: GALCANEZUMAB
6. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10906934 | GENENTECH, INC. | Protein purification methods |
Oct, 2033
(9 years from now) |
Ingredients: BEVACIZUMAB